IP Library Granted Patent US 7,016,725
Granted Patent B2
US 7,016,725 · App. 10/288,562 · Granted Mar 21, 2006

Method and apparatus for destroying dividing cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,016,725
App. No.
10/288,562
Granted
Mar 21, 2006
Kind
B2
Abstract

The present invention provides a method and apparatus for selectively destroying dividing cells in living tissue formed of dividing cells and non-dividing cells. The dividing cells contain polarizable intracellular members and during late anaphase or telophase, the dividing cells are connected to one another by a cleavage furrow. According to the present method the living tissue is subjected to electric field conditions sufficient to cause movement of the polarizable intracellular members toward the cleavage furrow in response to a non-homogenous electric field being induced in the dividing cells. The non-homogenous electric field produces an increased density electric field in the region of the cleavage furrow. The movement of the polarizable intracellular members towards the cleavage furrow causes the break down thereof which results in destruction of the dividing cells, while the non-dividing cells of the living tissue remain intact.

Claims (25)

1. A method for selectively destroying dividing cells in living tissue, the dividing cells having polarizable intracellular members, the method comprising the steps of:

subjecting the living tissue to a first electric field during late anaphase or telophase, wherein passage of the first electric field through the dividing cells in late anaphase or telophase transforms the field into a non-homogenous electric field, the non-homogenous electric field producing an increased density electric field in a region of a cleavage furrow, the non-homogenous electric field produced within the dividing cells being sufficient to create a condition within the dividing cells that increases the likelihood that the dividing cells are destroyed.

2. A method according to claim 1 , wherein the non-homogenous electric field is sufficient to move the polarizable intracellular members toward the cleavage furrow until the intracellular members disrupt the cleavage furrow causing destruction of the dividing cells, the cleavage furrow being in the form of a cytoplasm bridge membrane.

3. A method according to claim 1 , wherein the first electric field has a sufficient frequency so that the non-homogenous electric field produced in the dividing cells defines electric field lines which generally converge at a region of the cleavage furrow, thereby defining the increased density electric field.

4. A method according to claim 1 , wherein the step of subjecting the living tissue to the first electric field comprises the step of:

subjecting the living tissue to an alternating electric potential at a sufficient frequency to cause associated electric field lines to penetrate the dividing cells and form the non-homogenous electric field within the dividing cells.

5. A method according to claim 1 , wherein the step of transforming the first electric field into the non-homogenous electric field includes:

forming electric forces in the dividing cells which act to pull the polarizable intracellular members toward the increased density electric field region.

6. A method according to claim 1 , wherein the polarizable intracellular members are organelles.

7. A method according to claim 1 , wherein the step of subjecting the living tissue to the first electric field comprises the step of:

subjecting the living tissue to a pulsating alternating electric potential at a sufficient frequency to form the non-homogenous electric field within the dividing cells.

8. A method according to claim 1 , wherein the step of subjecting the living tissue to the first electric field comprises the step of:

subjecting the living tissue to an alternating electric potential at a frequency of about 200 kHz when the dividing cells are melanoma cells.

9. A method according to claim 1 , wherein the dividing cells comprise a first sub-cell and a second sub-cell with the cleavage furrow connecting the two in late anaphase or telophase.

10. A method according to claim 1 , wherein the step of subjecting the living tissue to the first electric field comprises the step of:

providing a first electrode;

providing a second electrode;

applying an alternating electric potential across the first and second electrodes, wherein the first and second electrodes are disposed in a vicinity of the living tissue to be treated.

11. A method according to claim 2 , wherein movement of the intracellular members toward the cleavage furrow increases pressure being exerted on the cleavage furrow, the increased pressure causing the region of the cleavage furrow to expand resulting in the cleavage furrow breaking apart and causing destruction of the dividing cells.

12. A method according to claim 1 , wherein the first electric field is a substantially uniform electric field.

13. A method for selectively destroying dividing cells in living tissue, the dividing cells containing polarizable intracellular members, the method comprising the step of:

subjecting the living tissue to first electric field conditions in late anaphase or telophase which is sufficient to cause displacement of the polarizable intracellular members towards a cleavage furrow connecting the dividing cells in response to a non-homogenous first electric field being induced in the dividing cells, the displacement of the polarizable intracellular members causing the break down of the cleavage furrow which results in the destruction of the dividing cells while non-dividing cells of the living tissue remain intact.

14. A method according to claim 13 , further including the steps of:

terminating the application of the first electric field; and

subsequently subjecting the living tissue to second electric field conditions which sufficient to cause displacement of the polarizable intracellular members towards the cleavage furrow in response to a non-homogenous second electric field being induced in the dividing cells, the non-homogenous second electric field being normal to the non-homogenous first electric field.

Assignments (15)
PATENT SECURITY AGREEMENT Recorded May 4, 2024
From: NOVOCURE GMBH (SWITZERLAND)
To: BIOPHARMA CREDIT PLC
Reel/Frame 067315/0399 →
RELEASE OF SECURITY INTEREST Recorded Apr 24, 2024
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NOVOCURE GMBH
Reel/Frame 067211/0839 →
SECURITY INTEREST Recorded Nov 6, 2020
From: NOVOCURE GMBH
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 054344/0510 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 45278 0825 Recorded Aug 25, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 053597/0335 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 50395/0398 Recorded Aug 19, 2020
From: BPCR LIMITED PARTNERSHIP
To: NOVOCURE GMBH
Reel/Frame 053538/0623 →
OMNIBUS CONFIRMATION OF ASSIGNMENT AGREEMENT Recorded May 21, 2020
From: BIOPHARMA CREDIT PLC
To: BPCR LIMITED PARTNERSHIP
Reel/Frame 052741/0173 →
RELEASE OF SECURITY INTEREST FOR PATENT SECURITY AGREEMENT FILED AT REEL/FRAME 045278/0825 Recorded Apr 14, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052391/0549 →
RELEASE OF SECURITY INTEREST Recorded Apr 13, 2020
From: BIOPHARMA CREDIT PLC
To: NOVOCURE LIMITED
Reel/Frame 052383/0705 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 20, 2019
From: NOVOCURE LIMITED
To: NOVOCURE GMBH
Reel/Frame 050110/0098 →
SECURITY INTEREST Recorded May 6, 2019
From: NOVOCURE GMBH
To: BIOPHARMA CREDIT PLC
Reel/Frame 050395/0398 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045284/0851 →
SECURITY INTEREST Recorded Feb 7, 2018
From: NOVOCURE LIMITED
To: BIOPHARMA CREDIT PLC
Reel/Frame 045278/0825 →
RELEASE OF SECURITY INTEREST Recorded Feb 7, 2018
From: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
To: NOVOCURE LIMITED
Reel/Frame 044858/0416 →
SECURITY INTEREST Recorded Feb 2, 2015
From: NOVOCURE LIMITED
To: BIOPHARMA SECURED INVESTMENTS III HOLDINGS CAYMAN LP
Reel/Frame 034866/0402 →
RELEASE OF SECURITY INTEREST Recorded Dec 20, 2013
From: DEUTSCHE BANK TRUST COMPANY AMERICAS
To: NOVOCURE LIMITED
Reel/Frame 031866/0567 →